Hemogenyx Pharmaceuticals PLC (HEMO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has a cash flow conversion efficiency ratio of -2.090x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.78 Million ≈ $-216.99 USD) by net assets (GBX853.49K ≈ $103.85 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HEMO stock market capitalisation for the company's overall valuation and market capitalisation.
Hemogenyx Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Hemogenyx Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hemogenyx Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Explore cash flow quality index of Hemogenyx Pharmaceuticals PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
SkinBioTherapeutics PLC
LSE:SBTX
|
-0.053x |
|
Provexis plc
LSE:PXS
|
-0.307x |
|
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
|
-0.003x |
|
SysGroup PLC
LSE:SYS
|
0.029x |
|
SCRYB INC.
F:EIY
|
N/A |
|
Wag! Group Co.
NASDAQ:PET
|
0.332x |
|
TUGA INNOVATIONS INC.
F:DQ5
|
0.025x |
Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals PLC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. View Hemogenyx Pharmaceuticals PLC (HEMO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX853.49K ≈ $103.85 |
GBX-4.12 Million ≈ $-500.91 |
-4.824x | -119.71% |
| 2023-12-31 | GBX2.78 Million ≈ $338.37 |
GBX-6.11 Million ≈ $-742.87 |
-2.195x | -144.66% |
| 2022-12-31 | GBX3.24 Million ≈ $394.64 |
GBX-2.91 Million ≈ $-354.14 |
-0.897x | -178.97% |
| 2021-12-31 | GBX8.17 Million ≈ $993.76 |
GBX-2.63 Million ≈ $-319.67 |
-0.322x | +84.34% |
| 2020-12-31 | GBX875.68K ≈ $106.55 |
GBX-1.80 Million ≈ $-218.81 |
-2.054x | -159.74% |
| 2019-12-31 | GBX-349.04K ≈ $-42.47 |
GBX-1.20 Million ≈ $-145.99 |
3.438x | +343.75% |
| 2018-12-31 | GBX959.17K ≈ $116.70 |
GBX-1.35 Million ≈ $-164.59 |
-1.410x | -563.74% |
| 2017-12-31 | GBX2.13 Million ≈ $259.39 |
GBX-452.98K ≈ $-55.11 |
-0.212x | +30.96% |
| 2016-12-31 | GBX903.71K ≈ $109.96 |
GBX-278.15K ≈ $-33.84 |
-0.308x | -30148.52% |
| 2015-12-31 | GBX77.82K ≈ $9.47 |
GBX79.71 ≈ $0.01 |
0.001x | -- |
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more